Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2015 - 2022)
Intellia Therapeutics (NTLA) reported Other Non-Current Liabilities of $24.0 million for Q4 2022, up 29.17% quarter-over-quarter from $18.6 million in Q3 2022.
Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2015 - 2022) Analysis & Trends
Intellia Therapeutics (NTLA) has 5 years of Other Non-Current Liabilities data on file, last reported at $24.0 million in Q4 2022.
- Other Non-Current Liabilities for Q4 2022 came in at $24.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $24.0 million (changed N/A YoY), and the FY2022 annual result was $24.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $24.0 million in Q4 2022 per NTLA's latest filing, from $18.6 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $24.0 million in Q4 2022 and troughed at $13000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 24.03 Mn |
| Sep 30, 2022 | 18.60 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 10.96 Mn |
| Dec 31, 2018 | 13,000.00 |
| Sep 30, 2018 | 52,000.00 |
| Jun 30, 2018 | 92,000.00 |
| Mar 31, 2018 | 131,000.00 |
| Dec 31, 2017 | 168,000.00 |
| Sep 30, 2017 | 201,000.00 |
| Jun 30, 2017 | 234,000.00 |
| Mar 31, 2017 | 378,000.00 |
| Dec 31, 2016 | 293,000.00 |
| Sep 30, 2016 | 306,000.00 |
| Jun 30, 2016 | 363,000.00 |
| Mar 31, 2016 | 349,000.00 |
| Dec 31, 2015 | 323,000.00 |